In light of these promising results, BAY2927088 received the breakthrough therapy designation (BTD) from the Food and Drug Administration (FDA) for the treatment of patients with advanced NSCLC with activating HER2 mutations [82]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.